AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02456532
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six months of nightly placebo
Trial: NCT00676871
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
Trial: NCT00676871
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
Trial: NCT00676871
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
Trial: NCT00676871
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
Trial: NCT00676871
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
Trial: NCT00676871
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
Trial: NCT01762787
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
Trial: NCT01762787
Drug: Placebo to aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
Trial: NCT01762787
Drug: Placebo to prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
Trial: NCT01121653
Drug: Magnogene ® (magnesium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
Trial: NCT00717093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Trial: NCT01259128
Drug: SER120 Nasal Spray 500 ng/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER120 Level 1
Trial: NCT01259128
Drug: SER120 nasal spray 750 ng/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER120 (750 ng/day)
Trial: NCT02555878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet will be administered orally once daily for 180 days.
Trial: NCT03625622
Drug: AR1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR1001 Active Oral Tablet
Trial: NCT03625622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT00676871
Drug: MEDI-538
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
Trial: NCT03235778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
Trial: NCT02543710
Drug: Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression.
Trial: NCT01492361
Drug: AMR101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel Assignment
Trial: NCT01492361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel Assignment
Trial: NCT01492361
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
Trial: NCT04696757
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine without surgery
Trial: NCT03527745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be obtained from Fagron, Germany.
Trial: NCT02574091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration for twice daily.
Trial: NCT03120000
Drug: PQR309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PQR309, 80mg or 60mg daily or intermittent dosing
Trial: NCT00622817
Drug: Epinephrine 1mg
RxNorm normalized name: EPINEPHRINE 1MG/ML INJ
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
Trial: NCT05988008
Drug: CCX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05988008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00536679
Drug: GSK163090 capsule, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
Trial: NCT00536679
Drug: GSK163090 Tablet, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
Trial: NCT00536679
Drug: GSK163090 Tablet, fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
Trial: NCT03109249
Drug: SPARC1613
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
Trial: NCT03109249
Drug: Reference1613
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
Trial: NCT00533897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
Trial: NCT01270516
Drug: HMB, hydroxymethylbutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
Trial: NCT01270516
Drug: EPA, eicosapentaenoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
Trial: NCT04188847
Drug: Chemotherapy plus apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6.
Trial: NCT02227862
Drug: Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
Trial: NCT02314546
Drug: saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - Control patients will receive intranasal saline.
Trial: NCT00587457
Drug: CAT-8015 5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Trial: NCT00587457
Drug: CAT-8015 10 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Trial: NCT00587457
Drug: CAT-8015 20 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Trial: NCT02994992
Drug: BAY 987516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
Trial: NCT01774474
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01106495
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
Trial: NCT00763022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
Trial: NCT02994992
Drug: SPF Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT00125424
Drug: AQUAVAN® (fospropofol disodium) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02019810
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02019810
Drug: Dobutamine and norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03643796
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
Trial: NCT03423641
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
Trial: NCT02371304
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02585843
Drug: Spironolactone 100mg
RxNorm normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days
Trial: NCT02585843
Drug: Spironolactone 25mg
RxNorm normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/day of spironolactone
Trial: NCT00977106
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single iv infusion
Trial: NCT00354887
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
Trial: NCT04736693
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid dispensing claim is used as the exposure group.
Trial: NCT00575406
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: i.v., 750 mg/m2, d1 of each treatment cycle
Trial: NCT00575406
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v., 50 mg/m2, d1 of each treatment cycle
Trial: NCT00575406
Drug: liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v., 50 mg/m2, d1 of each treatment cycle
Trial: NCT00575406
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p.o., 100mg, d1 - d5 of each treatment cycle
Trial: NCT03577509
Drug: ABCD
RxNorm normalized name: Pentavalent (ABCDE) botulinum toxoid vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
Trial: NCT00003078
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01261078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal 8 mg of bupivacaine only
Trial: NCT01261078
Drug: epinephrine 25
RxNorm normalized name: EPINEPHRINE 250MCG 300D ORAL INHL
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
Trial: NCT01261078
Drug: Epinephrine 50
RxNorm normalized name: epinephrine 500 MCG per 0.5 ML Injectable Solution
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
Trial: NCT01261078
Drug: epinephrine 100
RxNorm normalized name: Epinephrine 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
Trial: NCT02153398
Drug: D961H capsule 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02153398
Drug: D961H capsule 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00900237
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
Trial: NCT03535168
Drug: BAY1902607
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.
Trial: NCT03535168
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for BAY1902607
Trial: NCT00459225
Drug: Iron (ferrous sulfate)
RxNorm normalized name: Iron (Ferrous Sulfate)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
Trial: NCT01475838
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTV administered according to prescribing information FTC/TDF administered according to prescribing information
Trial: NCT01475838
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TDF (200/300 mg) administered according to prescribing information
Trial: NCT04168957
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets
Trial: NCT00602329
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00602329
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03236857
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
Trial: NCT02652754
Drug: Granexin® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
Trial: NCT01400425
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
Trial: NCT03204578
Drug: AB (Midazolam OD formulation/Dormicum)
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
Trial: NCT02194465
Drug: LY2623091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02194465
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02194465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01898416
Drug: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given.
Trial: NCT02480296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01373164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02433678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00631033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01605903
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
Trial: NCT01605903
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
Trial: NCT02385318
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00769392
Drug: Proparacaine Ophthalmic
RxNorm normalized name: proparacaine ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drops of Proparacaine on the eye, administered as described in the package insert
Trial: NCT00082563
Drug: Azithromycin/Chloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00806156
Drug: NKTR-102 q14d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-102 given on a q14 day schedule
Trial: NCT00806156
Drug: NKTR-102 q21d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-102 given on a q21 day schedule
Trial: NCT01463488
Drug: SAR113945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular